Peptides as NS3-serine protease inhibitors of hepatitis C virus

US7012066B2 · kind B2 · utility

Assignees

• SCHERING CORPORATION · US
• Dendreon Corporation · US

Inventors

• Anil K. Saksena · Upper Montclair, US
• Viyyoor M. Girijavallabhan · Parsippany, US
• Raymond G. Lovey · West Caldwell, US
• Edwin Jao · Hackettstown, US
• Frank Bennett · Piscataway, US
• Jinping L. Mc Cormick · Edison, US
• Haiyan Wang · Cranbury, US
• Russell E. Pike · Stanhope, US
• Stephane L. Bogen · Somerville, US
• Tin-Yau Chan · Edison, US
• Yi Liu · San Diego, US
• Zhaoning Zhu · Plainsboro, US
• F. George Njoroge · Hackettstown, US
• Ashok Arasappan · Bound Brook, US
• Tejal Parekh · Mountain View, US
• Ashit K. Ganguly · Upper Montclair, US
• Kevin X. Chen · Edison, US
• Srikanth Venkatraman · Fords, US
• Henry A. Vaccaro · South Plainfield, US
• Patrick A. Pinto · Mine Hill, US
• Bama Santhanam · Bound Brook, US
• Scott Jeffrey Kemp · San Diego, US
• Odile Esther Levy · San Diego, US
• Marguerita Lim-Wilby · Village of La Jolla, US
• Susan Y. Tamura · San Diego, US
• Wanli Wu · Edison, US
• Siska Hendrata · Kenilworth, US
• Yuhua Huang · Westfield, US

Key dates

• Filing date: Jul 19, 2001
• Grant date: Mar 14, 2006
• Expiry date: Dec 11, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.